Piedmont Hematology and Oncology Associates Piedmont Hem/Onc Assoc (2) — Winston-Salem, North Carolina

Piedmont Hematology and Oncology Associates Piedmont Hem/Onc Assoc (2) is a clinical research site located in Winston-Salem, North Carolina, United States 27103.

Crixeo Health Trust Score: 54/100 (POOR). This profile has not yet been claimed by the site owner.

Piedmont Hematology and Oncology Associates Piedmont Hem/Onc Assoc (2) has participated in 1 clinical trials.

Therapeutic areas: First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis.

Sponsors: Novartis Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 54/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Piedmont Hematology and Oncology Associates Piedmont Hem/Onc Assoc (2)?

Piedmont Hematology and Oncology Associates Piedmont Hem/Onc Assoc (2) has a Crixeo Trust Score of 54/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Piedmont Hematology and Oncology Associates Piedmont Hem/Onc Assoc (2) conducted?

Piedmont Hematology and Oncology Associates Piedmont Hem/Onc Assoc (2) has 1 clinical trials on record. Their work covers First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis.

Is Piedmont Hematology and Oncology Associates Piedmont Hem/Onc Assoc (2) accredited by Crixeo Health?

Piedmont Hematology and Oncology Associates Piedmont Hem/Onc Assoc (2) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Piedmont Hematology and Oncology Associates Piedmont Hem/Onc Assoc (2)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.